giredestrant
Roche’s Oral SERD Achieves Progression-Free Survival Milestone in Pivotal Breast Cancer Trial
Roche; oral SERD; giredestrant; progression-free survival; pivotal study; breast cancer; ER-positive; endocrine therapy; Phase III trial; advanced breast cancer